CRISPR’s casgevy soars, but access lags behind hype

By early 2026, Casgevy, developed by CRISPR Therapeutics as the world’s first approved CRISPR-based gene-editing therapy, demonstrated impressive commercial momentum, generating $43 million in Q1 revenue while treating over 500 patients globally. This early success was bolstered by clinical trial data showing that pediatric patients aged 5 to under 12 achieved complete freedom from severe vaso-occlusive crises for at least 12 months, underscoring the therapy’s robust efficacy in younger populations.

In a landmark regulatory expansion during July 2026, the FDA broadened Casgevy’s approval to include children as young as 2 years old with sickle cell disease and transfusion-dependent beta-thalassemia, enabling earlier therapeutic intervention and significantly enlarging the eligible patient pool. This milestone not only reflects growing confidence in Casgevy’s safety and efficacy but also aligns with CRISPR Therapeutics’ strategic push to address unmet pediatric needs in genetic blood disorders.

The commercial trajectory of Casgevy continued its upward climb into Q2 2026, with revenues soaring to $76 million, nearly doubling the previous quarter’s figures. This surge highlights accelerating market uptake fueled by the FDA’s expanded pediatric indication and mounting clinical validation, positioning Casgevy as a pioneering gene-editing therapy that is reshaping treatment paradigms for sickle cell disease and beta-thalassemia.

By mid-2026, CRISPR Therapeutics has strategically diversified its clinical pipeline beyond its established focus on blood disorders, aggressively advancing in vivo gene editing programs targeting prevalent chronic diseases such as hypertension and alpha-1 antitrypsin deficiency (AATD). This expansion is exemplified by the launch of Phase I trials for CTX340 and CTX460, which target the AGT and SERPINA1 genes respectively, complementing their existing Phase Ib candidate CTX310 for severe hypertriglyceridemia and refractory hypercholesterolemia. This broadening focus signals CRISPR's intent to address larger patient populations and chronic conditions, moving gene editing from rare diseases into mainstream therapeutic areas.

The gene editing field anticipates a watershed moment within the next three to five years with the first commercial approval of in vivo therapies, a milestone that would validate years of pipeline diversification and clinical progress. Industry leaders express excitement about programs like CRISPR's hepatitis B initiative, which exemplify the shift toward targeting widespread chronic conditions with significant patient impact. Achieving this success will require not only scientific breakthroughs but also coordinated collaboration with global regulatory bodies, including the FDA and international agencies, to ensure these transformative therapies gain broad, equitable access worldwide.

By early 2026, CRISPR Therapeutics fortified its financial foundation with $2.44 billion in cash and equivalents, bolstered by a convertible note issuance that underpins its ambitious innovation and clinical development plans through 2028. This robust liquidity positions the company to capitalize on upcoming data readouts and trial initiations, which are anticipated to cement its leadership in gene-based medicine while expanding market access and payer reimbursement internationally.

CRISPR Therapeutics’ commercial momentum gained remarkable traction in the first half of 2026, with CASGEVY generating $43 million in Q1 and soaring to $76.4 million in Q2—a 151% year-over-year surge—treating over 500 patients globally. This impressive revenue growth, alongside $10.2 million in collaboration-driven total revenue in Q2, not only reflects strong market uptake but also fuels positive investor sentiment, reinforcing confidence in the company’s growth trajectory despite a $91.2 million quarterly net loss.

Investor enthusiasm culminated in a notable 12.3% stock price jump in August 2026, driven by CASGEVY’s commercial success and anticipation of a catalyst-rich second half of the year. The company’s sustained financial strength—maintaining approximately $2.36 billion in cash and equivalents as of June 30—combined with better-than-expected quarterly results, has galvanized market confidence, underpinning ongoing innovation and clinical development efforts in gene editing therapies.

Despite the FDA's expansion of Casgevy gene therapy to children as young as two, real-world access remains severely constrained by the treatment's inherent complexity and the necessity for administration at specialized authorized centers. These centers, predominantly located within major academic hospitals, are geographically distant from many patients—especially those in rural areas—compounding the challenge of undergoing weeks-long hospital stays and managing serious risks like engraftment failure and infertility from conditioning chemotherapy. This limited infrastructure starkly contrasts with the groundbreaking nature of the therapy, underscoring a persistent gap between scientific innovation and practical healthcare delivery.

The prohibitive cost of Casgevy and similar sickle cell gene therapies, ranging from $2.2 million to $3.1 million per patient, coupled with inconsistent and often delayed insurance authorization, erects formidable financial barriers for many families. Although insurers technically cover these treatments, the arduous authorization processes disproportionately burden sickle cell patients—many of whom have limited resources to contest denials—thereby exacerbating existing health disparities. Federal initiatives, such as a Medicaid access model linking payment to treatment efficacy and adopted by 33 states, represent promising steps toward mitigating these challenges, especially given Medicaid's significant coverage of the sickle cell population.

Manufacturing capacity, rather than patient demand, has emerged as a critical bottleneck limiting the availability of sickle cell gene therapies. This constraint was highlighted by the 2025 sale of a company holding a landmark FDA approval for a mere $30 million, signaling underinvestment despite the therapies' transformative potential. Such production limitations, combined with the need for long-term safety monitoring over 15 years and early fertility preservation counseling, emphasize that while scientific breakthroughs have been achieved, the supporting healthcare infrastructure and commercial ecosystem remain underdeveloped—particularly for a disease predominantly affecting Black Americans that has historically suffered from neglect.